Palvella Therapeutics, Inc. Foreign Currency Transaction Gain (Loss), Unrealized
Palvella Therapeutics, Inc. (PVLA) reported Foreign Currency Transaction Gain (Loss), Unrealized of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2022-03-02
- Palvella Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Palvella Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2020 was $8.00K, a 86.89% decline from fiscal 2019.
- Palvella Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2019 was $61.00K.
- Palvella Therapeutics, Inc. foreign currency transaction gain (loss), unrealized for fiscal 2018 was -$22.00K.
| Period end | Foreign Currency Transaction Gain (Loss), Unrealized 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-02 |
| 2020-12-31 | $8.00K 10-K · filed 2022-03-02 |
| 2019-12-31 | $61.00K 10-K · filed 2021-03-31 |
| 2018-12-31 | -$22.00K 10-K · filed 2020-03-13 |
| 2017-12-31 | -$156.00K 10-K · filed 2019-03-18 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |